🇺🇸 FDA
Patent

US 10047148

Neutralizing GP41 antibodies and their use

granted A61KA61K2039/505A61K39/42

Quick answer

US patent 10047148 (Neutralizing GP41 antibodies and their use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 14 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 09 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K2039/505, A61K39/42, A61K45/06, A61K49/0004